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Defining MC1R Regulation in Human Melanocytes
by Its Agonist a-Melanocortin and Antagonists
Agouti Signaling Protein and b-Defensin 3
Viki B. Swope1, Joshua A. Jameson1, Kevin L. McFarland2, Dorothy M. Supp2, William E. Miller3,
Dennis W. McGraw4, Mira A. Patel5, Matthew A. Nix5, Glenn L. Millhauser5, George F. Babcock2
and Zalfa A. Abdel-Malek1
The melanocortin 1 receptor (MC1R), a Gs protein–coupled receptor, has an important role in human pigmen-
tation. We investigated the regulation of expression and activity of the MC1R in primary human melanocyte
cultures. Human b-defensin 3 (HBD3) acted as an antagonist for MC1R, inhibiting the a-melanocortin
(a-melanocyte-stimulating hormone (a-MSH))–induced increase in the activities of adenylate cyclase and
tyrosinase, the rate-limiting enzyme for melanogenesis. a-Melanocortin and forskolin, which activate adenylate
cyclase, and 12-O-tetradecanoylphorbol-13-acetate, which activates protein kinase C, increased, whereas
exposure to UV radiation reduced, MC1R gene and membrane protein expression. Brief treatment with a-MSH
resulted in MC1R desensitization, whereas continuous treatment up to 3 hours caused a steady rise in cAMP,
suggesting receptor recycling. Pretreatment with agouti signaling protein or HBD3 prohibited responsiveness to
a-MSH, but not forskolin, suggesting receptor desensitization by these antagonists. Melanocytes from different
donors expressed different levels of the G protein–coupled receptor kinases (GRKs) 2, 3, 5, and 6, as well as b-
arrestin 1. Therefore, in addition to the MC1R genotype, regulation of MC1R expression and activity is expected
to affect human pigmentation and the responses to UV.
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INTRODUCTION
Skin and hair color are the outcome of synthesis of the dark
brown pigment eumelanin and the yellow-red pigment
pheomelanin by melanocytes, and skin pigmentation correlates
directly with eumelanin content (Hennessy et al., 2005; Hauser
et al., 2006). In mammals, including humans, eumelanin
synthesis in melanocytes is regulated primarily via activation
of the melanocortin 1 receptor (MC1R) by its agonist a-
melanocortin (a-melanocyte-stimulating hormone (a-MSH))
(Geschwind et al., 1972; Hunt et al., 1995). Genetic studies in
mice showed that loss-of-function mutations in Mc1r result in a
yellow coat color owing to lack of eumelanin synthesis (Tamate
and Takeuchi, 1984; Robbins et al., 1993). A similar coat color
phenotype results from mutations that cause overexpression of
agouti, which encodes agouti signaling protein (ASIP), the
physiological antagonist of the Mc1r (Silvers, 1979; Yen et al.,
1994; Abdel-Malek et al., 2001). This paradigm is recapitulated
in humans. In human melanocytes, allelic variants ofMC1R that
result in loss of function of the receptor are strongly associated
with red hair phenotype because of inhibition of eumelanin
synthesis that is normally induced by a-MSH (Box et al., 1997;
Smith et al., 1998; Scott et al., 2002a, b; Ringholm et al.,
2004; Kadekaro et al., 2010). Treatment of human melano-
cytes with ASIP blocks the binding of a-MSH to its receptor,
thus inhibiting eumelanin synthesis (Suzuki et al., 1997).
Recently, a new regulator of MC1R activity, CBD103, the
canine homolog of human b-defensin 3 (HBD3), was
discovered and found to bind to the MC1R with high affinity,
and to regulate pigmentation in dogs and transgenic mice
(Candille et al., 2007). The black coat color of HBD3 transgenic
mice was attributed to competition with ASIP binding to the
MC1R (Candille et al., 2007). The exact role of HBD3 in
regulating human MC1R activity remained to be determined.
The MC1R gene is highly polymorphic, with at least 75
different allelic variants identified in different human
populations (Garcia-Borron et al., 2005). On the basis of this
property, the MC1R is considered an important determinant
of the diversity of human pigmentation. This gene encodes a
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Gs protein–coupled receptor (GPCR) with seven transmem-
brane domains (Mountjoy et al., 1992). Some allelic variants
of the MC1R affect skin and hair color by impairing binding
of agonists to the MC1R, or inhibiting the activation of the
agonist-bound receptor. In particular, three variants, R151C,
R160W, and D294H, result in loss of function of the receptor
owing to lack of receptor signaling, and are strongly
associated with red hair color (Scott et al., 2002a, b;
Kadekaro et al., 2010). In addition, certain MC1R variants
affect the desensitization of the receptor and its trafficking to
the cell membrane (Beaumont et al., 2005; Sanchez-Mas
et al., 2005; Sanchez-Laorden et al., 2006).
Generally, GPCRs undergo homologous desensitization
after stimulation with agonist. Desensitization results from
phosphorylation of the receptors by the serine–threonine
kinases, GPCR kinases (GRKs), cAMP-dependent protein
kinase A (PKA), or protein kinase C (Bunemann and Hosey,
1999; Ferguson, 2001; Reiter and Lefkowitz, 2006; Premont
and Gainetdinov, 2007). Receptor phosphorylation leads to
recruitment of b-arrestin 1 and 2, which inhibit G protein
coupling and serve as adaptors linking the receptors to the
endocytic machinery. Previous studies on MC1R desensitiza-
tion were carried out on human melanoma cells expressing
endogenous MC1R, or cells (melanoma or human embryonic
kidney cells) transfected with human MC1R. Human mela-
nocytes express relatively low numbers of MC1R on their
surface (Donatien et al., 1992). Until now, it remained
unknown whether the desensitization process has a signifi-
cant role in regulating MC1R when it is expressed at phys-
iological levels in human melanocytes. The main goal of this
study was to investigate the regulation of MC1R expression
and activity by its physiological agonists and antagonists, and
by UV. We demonstrate the effects of HBD3 and the
regulation of MC1R expression and desensitization, which
to our knowledge were not previously reported in primary
human melanoctyes.
RESULTS
To define the role of HBD3 in regulating MC1R signaling in
primary human melanocytes, the effects of HBD3 on cAMP
levels, proliferation, and tyrosinase activity in the absence or
presence of a-MSH were determined and compared with
those of the known MC1R physiological antagonist ASIP.
Treatment of melanocytes with 1, 10, or 100 nM HBD3 had
no effect on cAMP formation (Figure 1a). When melanocytes
were treated concomitantly with 1 nM a-MSH, and 1, 10, or
100 nM HBD3, only the highest concentration of HBD3
resulted in significant inhibition of the a-MSH–induced
increase in cAMP levels. On the basis of these results, we
used 100 nM HBD3 to demonstrate its antagonistic effects on
the a-MSH–induced stimulation of cAMP formation, prolif-
eration, and tyrosinase activity. As shown in Figure 1b and c,
concomitant treatment of a different melanocyte strain with
1 nM a-MSH and 100nM HBD3 totally abrogated the effect of
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Figure 1. Effect of human b-defensin 3 (HBD3) on basal and a-melanocyte-stimulating hormone (a-MSH)–induced cAMP levels, proliferation, and tyrosinase
activity. (a) Melanocytes were treated with 0, 1 nM a-MSH, or 1, 10, or 100 nM HBD3±1 nM a-MSH for 45minutes. *Significantly different from control at
Po0.01, or #from a-MSH at Po0.05. (b) Melanocytes were treated with 100 nM HBD3±1 nM a-MSH or 1 mM forskolin, or 100 nM agouti signaling protein
(ASIP)±1nM a-MSH for 45minutes. *Statistically different from control at Po0.001. (c) Melanocytes were treated for 6 days with the same concentrations of
a-MSH and/or HDB3 or ASIP as in (b). *Significantly different from control at Po0.05, or #from a-MSH at Po0.001. Data represent mean percentage of
control±SEM. Triplicate experiments were performed.
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a-MSH on cAMP levels, and markedly inhibited its effect on
proliferation and tyrosinase activity. HBD3 did not reduce the
forskolin-induced stimulation of cAMP production, suggest-
ing that HBD3 does not directly inhibit adenylate cyclase
(Figure 1b). As we have previously reported, ASIP markedly
abolished the stimulatory effects of a-MSH on cAMP levels,
proliferation, and tyrosinase activity (Figure 1b and c; Suzuki
et al., 1997). In this study, we used the fully MC1R-active,
cysteine-rich domain ASIP (80-132), with two mutations to
enhance folding and stability (McNulty et al., 2005; referred
to throughout as ASIP). Treatment with 100 nM HBD3 had no
effect, but significantly inhibited the stimulatory effects of 1nM
a-MSH on cell proliferation and tyrosinase activity (Figure 1c).
To investigate the transcriptional regulation of MC1R
expression, we performed quantitative real-time reverse-
transcriptase–PCR on RNA isolated from melanocytes that
were treated with 1nM a-MSH, 1mM forskolin, 100nM HBD3
or ASIP, or irradiated with 75 or 105mJ cm2 UV (Figure 2).
Treatment with a-MSH increased the expression ofMC1R after
8 hours. Forskolin also upregulatedMC1R expression, suggest-
ing that activation of the cAMP pathway is involved in
transcriptional regulation of this gene. Neither HBD3 nor ASIP
had any effect, whereas irradiation with UV resulted in a
marked reduction of MC1R expression. The effects of UV, a-
MSH, forskolin, and 12-O-tetradecanoylphorbol-13-acetate
were confirmed by immunostaining of the membrane-bound
MC1R in viable melanocytes followed by flow cytometric
analysis (Figure 3). We found that exposure to UV resulted in
significant and dose-dependent reduction, which was evident
24hours post irradiation, whereas a-MSH, forskolin, or 12-O-
tetradecanoylphorbol-13-acetate significantly increased MC1R
membrane expression 14hours after treatment (Figure 3).
Generally, GPCRs undergo desensitization upon pro-
longed or repeated exposure to their respective agonists.
We found that the MC1R underwent desensitization after
20minutes of treatment with 1 nM a-MSH (Figure 4a). The
inability of melanocytes to respond to retreatment with a-
MSH with further increase in cAMP suggests homologous
desensitization. Melanocytes could still respond to forskolin
following brief treatment with a-MSH, indicating that
adenylate cyclase could still be activated. Pretreatment
of melanocytes with 1 nM HBD3 or ASIP for 20minutes
prevented melanocytes from responding to a challenge with
1 nM a-MSH (Figure 4a). However, melanocytes pretreated
with 100 nM HBD3 or ASIP responded to forskolin, suggesting
that these antagonists affect the MC1R and not adenylate
cyclase (Figure 4b). Continuous treatment with a-MSH
for 3 hours resulted in a greater increase in cAMP levels
than brief treatment for 45minutes, suggesting that
although MC1R undergoes desensitization the receptors
might be rapidly recycled and that the agonist might enhance
the trafficking of receptors to the cell surface (Figure 4c).
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Figure 2. Regulation of melanocortin 1 receptor (MC1R) gene expression by
a-melanocyte-stimulating hormone (a-MSH), agouti signaling protein (ASIP),
human b-defensin 3 (HBD3), and UV. Melanocytes were maintained in
medium lacking 12-O-tetradecanoylphorbol-13-acetate and bovine pituitary
extract overnight, and then treated with 0, 1 nM a-MSH, 1mM forskolin, 100 nM
HBD3 or ASIP, or irradiated with 75 or 105mJ cm2 UV. Total RNA was
isolated 8hours after treatment, and equal amounts of RNA from each group
were analyzed by quantitative real-time reverse-transcriptase–PCR. Similar
results were obtained in two independent experiments using two different
melanocyte strains. The data were normalized using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a loading control, and mean relative
expression levels are presented±SEM. *Statistically different from control at
Po0.001.
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Figure 3. Regulation of cell surface expression of melanocortin 1 receptor (MC1R) by a-melanocyte-stimulating hormone (a-MSH) and UV, as
determined by immunostaining for MC1R followed by flow cytometric analysis. (a) Melanocytes were irradiated with increasing doses of UV (0, 20, 50,
75, or 105mJ cm2) and immunostained for MC1R 24 hours after exposure. (b) Melanocytes were treated with 0, 1 nM a-MSH, 1 mM forskolin, or 5 ng/ml
12-O-tetradecanoylphorbol-13-acetate (TPA) for 14 hours. In (a, b), the data (percentage of control±SEM) represent the combined results of three independent
experiments. *Statistically different from control at Po0.05.
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However, after 6 hours of continuous treatment with a-MSH,
cAMP levels decreased, presumably owing to uncoupling of
the receptor from Gs protein (Figure 4c).
Activation of PKA is thought to be a mechanism for GPCR
desensitization. To investigate the potential role of PKA in this
process, we compared MC1R desensitization in the presence
or absence of the PKA inhibitor H-89. The results revealed
that inhibition of PKA did not alleviate the a-MSH–induced
MC1R desensitization, suggesting that this process is
mediated by alternative mechanism(s), mainly by GRKs and
b-arrestins (Figure 4d).
Ten different melanocyte strains, each from a single donor,
were used to compare the expression of GRK2, 3, 5, and 6, as
well as b-arrestin 1, by western blot analysis (Figure 5). We
found that all 10 strains expressed relatively similar levels of
GRK2 and b-arrestin 1, showed some variation in GRK3
levels, but differed tremendously in the expression of GRK5
and 6. These results were confirmed in additional nine
melanocyte strains. The levels of GRKs did not correlate
with the pigmentary phenotype or theMC1R genotypes of the
donors (data not shown). Treatment with 1 or 10 nM a-MSH,
ASIP, or HBD3 for 45, 60, or 90minutes had variable effects
on the levels of GRK2, 3, 5, and 6 in different melanocyte
strains (data not shown). When increases in the levels of
GRKs were observed, the kinetics and extent of the effects
differed among the different strains tested, reflecting possible
individual differences in desensitization.
DISCUSSION
The MC1R gene is a principal regulator of the diversity of
human pigmentation and a melanoma susceptibility gene
(Box et al., 1997, 2001; Smith et al., 1998; Palmer et al.,
2000; Kennedy et al., 2001; Garcia-Borron et al., 2005). We
have demonstrated that this gene has a central role in the UV
response of human melanocytes (Im et al., 1998; Kadekaro
et al., 2005, 2010). Elucidating how expression and activity
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Figure 4. Response to a-melanocyte-stimulating hormone (a-MSH) after pretreatment with agonist or antagonists, and the role of protein kinase A in
melanocortin 1 receptor desensitization. Data represent percentage of control±SEM. (a) In 10 independent experiments, melanocytes were pretreated with 0,
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*Statistically different from control, þ from the 45-minute a-MSH treatment, or #from the 3-hour a-MSH treatment at Po0.05. (d) Melanocytes were pretreated
with 0, or 1 nM a-MSH±100 nM H-89. This experiment was repeated twice with similar findings. *Statistically different from control or #from the 20-minute
a-MSH treatment at Po0.01. Forsk, forskolin; Tx, treatment.
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of this receptor are regulated is pivotal for understanding its
effects on melanocytes and the risk for melanoma. Unlike
other GPCRs, the MC1R, MC3R, and MC4R have physiolo-
gical agonists and antagonists, with a-MSH being the agonist
for all three receptors, ASIP the antagonist for MC1R, and
agouti-related protein the antagonist for MC3R and MC4R
(Ollmann et al., 1997; Suzuki et al., 1997). b-Defensin 3, best
known for its antimicrobial activity and role in innate
immunity (Harder et al., 2001), was recently found to bind
to the MC1R and induce black coat color in domestic dogs
and transgenic mice (Candille et al., 2007). We tested the
effects of HBD3 on cultured human melanocytes and found
that it inhibited the stimulatory effects of a-MSH on cAMP
formation, tyrosinase activity, and proliferation (Figure 1a
and c). Previously, it was shown that HBD3 alone had no
effect on basal levels of cAMP in heterologous cells
expressing the MC1R, but abrogated the effect of the potent
melanocortin analog NDP-MSH on cAMP levels (Beaumont
et al., 2011). HBD3 is synthesized by keratinocytes, and thus
functions as a paracrine factor for melanocytes (Harder et al.,
2001). Sawamura et al. (2005) reported that HBD3 in normal
skin was mainly localized in the spinous and granular layers;
however, Kesting et al. (2010) clearly showed HBD3
immunolocalization throughout the epidermis, with in-
creased expression in wounded skin. Comparison of HBD3
expression by a panel of primary human keratinocytes
showed no correlation with the donor’s pigmentary pheno-
type (data not shown), suggesting that HBD3 is not a direct
determinant of constitutive pigmentation. We found that
HBD3 markedly inhibited a-MSH–induced, but not the
forskolin-induced, increase in cAMP levels, strongly suggest-
ing that its inhibitory effect is mediated by blocking the MC1R
(Figure 1b). The results hereby presented identify a role for
HBD3 as a physiological antagonist for the MC1R, which can
modulate the effects of a-MSH on human pigmentation and
consequently the UV response.
Previously, we reported results of northern blot analysis
showing that treatment of cultured human melanocytes
by a-MSH increased, whereas exposure to UV reduced,
MC1R mRNA levels (Scott et al., 2002a, b). Here, we used
quantitative real-time reverse-transcriptase–PCR to further
investigate the regulation of MC1R gene expression by its
physiological agonists and antagonists and UV (Figure 2).
Results showed that treatment of melanocytes with a-MSH
upregulated, whereas exposure to UV markedly downregu-
lated, MC1R gene expression. As expected, treatment with
ACTH had similar effects as a-MSH (data not shown). These
findings are consistent with our microarray data showing
reduction of MC1R expression by UV and increased expres-
sion by a-MSH (Kadekaro et al., 2010). Treatment with either
ASIP or HBD3 had no effect on MC1R gene expression
(Figure 2). Previously, we reported that low to moderate doses
of UV had a transient inhibitory effect on MC1R mRNA levels
(Scott et al., 2002a, b). Accordingly, we expect the inhibitory
effect of the low doses of UV used in the current experiments
(20–75mJ cm2 UV; Figure 3a) to be short lived. By
immunostaining of viable melanocytes with MC1R-specific
antibody followed by flow cytometric analysis, we verified
that exposure to UV markedly decreased, whereas treatment
with a-MSH, forskolin, or 12-O-tetradecanoylphorbol-13-
acetate increased, MC1R cell surface expression (Figure 3).
The discrepancy between our results, that UV reduced MC1R
expression, and those previously reported by Funasaka et al.
(1998), that UV upregulated MC1R expression, can possibly
be attributed to different culture conditions of melanocytes,
experimental protocols, and the UV source used. Our results
unequivocally demonstrate that MC1R expression is upregu-
lated by its agonists, and suggest that activation of PKA and
protein kinase C is involved in this process.
The MC1R belongs to the large family of GPCRs, which
are activated by their cognate ligand that causes conforma-
tional changes of the receptor, leading to signaling via
heterotrimeric G proteins (Bunemann and Hosey, 1999;
Premont and Gainetdinov, 2007). The activation of GPCRs is
turned off by the complex process of homologous desensi-
tization. This process is initiated by GRKs that phosphorylate
serine and threonine residues in the third intracellular loop or
carboxy-terminal domains of the activated GPCR (Ferguson,
2001; Premont and Gainetdinov, 2007). Phosphorylated
GPCRs have a high affinity to members of the arrestin family,
which bind to the receptors, uncouple them from hetero-
trimeric G proteins, and target them for internalization via
clathrin-coated vesicles. It has been reported that MC1R
expressed by human or mouse melanoma cells or by
heterologous human embryonic kidney cells undergo desen-
sitization (Sanchez-Mas et al., 2005; Sanchez-Laorden et al.,
2006). However, MC1R desensitization has not yet been
investigated in human melanocytes, which express low
numbers of the receptor (Donatien et al., 1992), and differ
from human embryonic kidney cells in GRK expression
(data not shown). In addition, human and mouse melanoma
cells were found to express GRK2 and GRK6 only (Sanchez-
Mas et al., 2005), whereas human melanocytes express
GRK2, 3, 5, and 6 (Figure 5). These differences underscore
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the importance of investigating MC1R desensitization by the
endogenous cellular machinery in human melanocytes, as
reported for other GPCRs (Bunemann and Hosey, 1999;
Premont and Gainetdinov, 2007).
Using 10 different melanocyte strains, we found that
MC1R underwent homologous desensitization in all (Figure
4a). Brief pretreatment with agonist or the antagonists ASIP or
HBD3 did not result in heterologous desensitization, as
evidenced by the ability to respond to forskolin, indicating
that adenylate cyclase was not desensitized (Figure 4a and b).
Continuous treatment with a-MSH for 3 hours resulted in
greater increase in cAMP levels than treatment for 45minutes
(Figure 4c), suggesting rapid receptor recycling. These results
and the fact that the MC1R lacks Ser–Thr-rich clusters in its
third intracellular loop and C terminus (Reiter and Lefkowitz,
2006) suggest that MC1R belongs to class A of GPCRs that
interact transiently with b-arrestins, internalize with them into
clathrin-coated pits, dissociate, and are rapidly recycled.
Besides GRKs, PKA might also be involved in MC1R
desensitization. However, in human melanocytes, the PKA
inhibitor H-89 did not block the a-MSH–induced MC1R
desensitization, suggesting that PKA activation does not
mediate this process (Figure 4d). In this regard, the MC1R
differs from the MC2R expressed in mouse adrenal tumor
cells and MC4R expressed in mouse hypothalamic cells,
both of which undergo PKA-mediated receptor desensitiza-
tion and internalization, which are inhibited by treatment
with H-89 (Baig et al., 2001; Shinyama et al., 2003; Kilianova
et al., 2006).
Our results suggest that binding of the antagonists ASIP
and HBD3 to the MC1R is an important mechanism for
regulating receptor activity. Studies on heterologous cells
transfected with the MC3R or MC4R showed that binding of
these receptors by the synthetic inhibitor SHU-9119 resulted
in retention of the antagonist–receptor complex on the cell
surface, whereas treatment with agonist caused agonist–
receptor internalization (Cai et al., 2006). We show that
pretreatment with either ASIP or HBD3, which we found to
be an antagonist for MC1R, blocked the responsiveness of
melanocytes to a-MSH, suggesting that these two antagonists
enhance receptor internalization, inhibit its recycling, and/or
have prolonged receptor occupancy.
By using western blot analysis, we compared the expres-
sion of the GRK2, 3, 5, and 6, as well as b-arrestin 1, in a
panel of melanocyte strains with different melanin contents
(Figure 5). We did not investigate the expression of GRK1, 7,
or 4, as the former two are predominantly expressed in the
retina, whereas GRK4 is mainly expressed in the testis
(Pitcher et al., 1998). We observed that melanocyte strains
derived from different donors express the ubiquitous GRK2,
3, 5, and 6, as well as b-arrestin 1 (Figure 5). Expression of
GRK2 and b-arrestin 1 was the least variable, followed by
expression of GRK3, whereas expression of GRK5 and 6
varied markedly among the different strains. Expression of
GRKs and b-arrestin 1 was not dependent on the MC1R
genotype, as melanocytes expressing two red hair alleles that
result in loss of function of MC1R (830C and 1307C) had
similar levels of expression as strains with functional MC1R
(e.g., 1292C). Interestingly, two adult melanocyte strains with
high melanin content had the least expression of GRK3, and
very low levels of GRK5 and GRK6 (AHM 108B in Figure 5,
and data not shown).
We found that treatment of different human melanocyte
strains (n¼ 7) with 10 nM of the agonist a-MSH, HBD3, or
ASIP for 45minutes, 1 hour, or 90minutes had variable
effects on the levels of GRK2, 3, 5, and 6 (data not shown).
This variability might explain the differential responses of
different melanocyte strains to continuous treatment with
a-MSH, in that some cAMP levels returned to basal levels,
whereas in others the levels were reduced but remained
significantly high after 6 hours of treatment (Figure 4c). This
might possibly be due to a greater increase in GRK levels,
resulting in more desensitization and/or less resensitization of
MC1R in the former compared with the latter. In future
experiments, more detailed time-course experiments will be
conducted to determine the effects of the MC1R agonist and
antagonists on GRKs, and to correlate these effects with the
levels of cAMP induced by a-MSH treatment.
Our results identify HBD3 as an antagonist of the MC1R
that is expressed in human melanocytes and shed new light
on the regulation of MC1R expression and activity by its
agonist and antagonists. The fact that UV reduces, whereas a-
MSH upregulates, MC1R expression underscores the signifi-
cance of this agonist in upregulating the MC1R, which is
critical for the proper DNA damage response of melanocytes
to UV (Kadekaro et al., 2005, 2010). Our findings demon-
strate that a-MSH causes MC1R desensitization, which seems
to be transient, and show that the MC1R antagonists ASIP and
HBD3 inhibit MC1R activity by blocking its activation by
a-MSH, and possibly causing MC1R desensitization. In addition
to the known effects of differentMC1R genotypes, the present
findings identify additional mechanisms that modulate MC1R
expression and activity, and thus affect human pigmentation
and the UV response.
MATERIALS AND METHODS
Primary melanocyte cultures
Human melanocyte cultures were established from neonatal fore-
skins or discarded surgery-derived adult skin, as previously described
(Suzuki et al., 1996). The protocol for obtaining these tissues was
deemed exempt by the University of Cincinnati Institutional Review
Board.
Response of melanocytes to HBD3
To determine the effects of HBD3 on cAMP levels, melanocytes were
treated with 1, 10, or 100nM HBD3 in the presence or absence of
1 nM a-MSH, or, alternatively, with 100nM HBD3 and 1mM forskolin
for 45minutes, and cAMP levels were determined using the radio-
immunoassay kit (Perkin Elmer, Waltham, MA) as described (Suzuki
et al., 1996). Included in these experiments were two groups, one
treated only with 100nM ASIP and another treated with 100nM ASIP
and 1nM a-MSH. The effects of HBD3 or ASIP on melanocyte
proliferation and tyrosinase activity were determined following 6
days of treatment with 100nM HBD3 or with ASIP with or without
1 nM a-MSH, with the medium and treatment replenished every other
day, as described in Abdel-Malek et al. (1995). Cell numbers were
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determined using a Coulter Counter. Triplicate samples were
included in each group and normalized to untreated control.
Quantitative reverse transcriptase PCR
To investigate the transcriptional regulation of MC1R by its agonists,
antagonists, and UV, melanocytes were treated with 1 nM a-MSH,
1mM forskolin, 100 nM ASIP or HBD3, or irradiated with 75 or
105mJ cm2 UV. Total RNA was extracted 8 hours after treatment or
post UV using the RNeasy Mini Kit combined with the RNase-free
DNase system (Qiagen, Valencia, CA). First-strand cDNA was
synthesized using 2.5 mg of total RNA using the SuperScript VILO
Synthesis Kit (Invitrogen, Carlsbad, CA), and quantitative real-time
reverse-transcriptase–PCR was performed using human MC1R and
glyceraldehyde-3-phosphate dehydrogenase RT2 qPCR Primers and
RT2 SYBR Green/Fluorescein PCR Master Mix (SABiosciences/
Qiagen, Valencia, CA). Amplification was performed using the
BIO-RAD iCycler iQ system (BioRad, Hercules, CA). The cycle
threshold values were determined using the iCycle iQ system
software (BioRad), and the comparative DDCT method was used to
calculate the relative MC1R expression levels after normalization to
glyceraldehyde-3-phosphate dehydrogenase (Livak and Schmittgen,
2001). Biological triplicates were processed individually for RNA
isolation and analyzed in technical triplicate. Values were normal-
ized to expression in control melanocytes.
Flow cytometry
Regulation of MC1R expression on the melanocyte cell membrane
by 0, 20, 50, 75, or 105mJ cm2 UV was determined 24hours post
irradiation. Regulation of MC1R by 1nM a-MSH, 1 mM forskolin, or
5 ngml1 12-O-tetradecanoylphorbol-13-acetate was determined
14 hours after treatment. Viable melanocytes were harvested using
5mM EDTA at 4 1C, and all staining steps were carried out on ice.
Cells were blocked with normal goat serum and then incubated with
rabbit anti-MC1R (H-60, Santa Cruz Biotechnology, Santa Cruz, CA)
for 1 hour. Following washes, the cells were incubated with goat
anti-rabbit IgG Quantum Dot 655 (Invitrogen) and then postfixed
with 1% paraformaldehyde. Negative controls consisted of immuno-
staining with secondary antibody and no primary antibody, and
rabbit IgG isotype control (Imgenex, San Diego, CA). Cells were
analyzed using a BD LSRII flow cytometer (Becton-Dickinson,
San Jose, CA). A total of 10,000 events were collected for each sample.
MC1R desensitization
For receptor desensitization, melanocytes were pretreated for
20minutes with 1 nM a-MSH, 1 nM ASIP or HBD3, washed once,
and then incubated for 2 hours in medium lacking a-MSH or
antagonist, followed by retreatment for 45minutes with 1 nM a-MSH.
The following groups were also included: treatment with 1 mM
forskolin for 20minutes, and pretreated with 100 nM ASIP or HBD3
as described above, then challenged with forskolin for 45minutes.
Melanocytes were also treated continuously for 45minutes, 3 hours,
or 6 hours with 1 nM a-MSH. To determine the role of PKA in MC1R
desensitization, melanocytes were treated concomitantly with 1 nM
a-MSH and 100nM H-89, a PKA inhibitor for 20minutes, followed
by washing and incubation in medium containing only H-89 for
2 hours, and then treating with a-MSH and H-89 for 45minutes.
Following each of these treatments, cAMP levels were determined
using a radioimmunoassay. Triplicates were included in each group.
Western blot analysis for GRKs
Expression of GRK2, 3, 5, and 6, as well as b-arrestin 1, was
compared by western blotting using protein extracts derived from
10 different human melanocyte strains with different pigmentary
phenotypes and MC1R genotypes. The following antibodies were
used: SC-562, clone C-15 for detection of GRK2, SC-563, clone C-14
for GRK3, SC-565, clone C-20 for visualization of GRK5, and
SC-566, and clone C-20 for GRK6 (Santa Cruz, CA). The antibody
for b-arrestin is a rabbit antibody raised against a glutathione
S-transferase-b-arrestin fusion protein.
Statistical analysis
Statistical analysis was carried out on triplicate samples per group
using a one-way analysis of variance followed by Newman–Keuls
multiple comparison test.
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